Learn More
CD134 (OX40) Monoclonal Antibody (ACT35 (ACT-35)), Biotin, eBioscience™, Invitrogen™
Mouse Monoclonal Antibody
£110.00 - £216.00
Specifications
| Antigen | CD134 (OX40) |
|---|---|
| Clone | ACT35 (ACT-35) |
| Concentration | 5 μL/Test |
| Applications | Flow Cytometry |
| Classification | Monoclonal |
| Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
|---|---|---|---|---|---|---|---|---|---|
| Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
|
17170392
|
eBioscience
13-1347-41 |
25 Tests | |||||||
|
17180392
|
eBioscience
13-1347-42 |
100 Tests |
£216.00
Pack of 100 |
Please sign in to purchase this item. Need a web account? Register with us today! | |||||
Description
Description: The ACT35 monoclonal antibody reacts with human CD134, also known as OX-40. A member of the TNF receptor superfamily, CD134/OX-40 is a 50 kDa type I membrane glycoprotein expressed by activated T lymphocytes. The interaction of CD134 with OX-40L has been implicated in T cell-dependent humoral response, regulation of primary T cell expansion, survival of T cells, size of the memory T cell pool and regulation of tolerance in the CD4^+ T cell compartment. Applications Reported: This ACT35 (ACT-35) antibody has been reported for use in flow cytometric analysis. Applications Tested: This ACT35 (ACT-35) antibody has been pre-diluted and tested by flow cytometric analysis of stimulated normal human peripheral blood cells. This may be used at 5 μL (0.25 μg) per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.
OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system. When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents. OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer. They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.Specifications
| CD134 (OX40) | |
| 5 μL/Test | |
| Monoclonal | |
| Liquid | |
| RUO | |
| P43489 | |
| IgG1 κ | |
| Antibody |
| ACT35 (ACT-35) | |
| Flow Cytometry | |
| Biotin | |
| Mouse | |
| Human | |
| 7293 | |
| Primary |
Your input is important to us. Please complete this form to provide feedback related to the content on this product.